海正药业(600267.SH)：子公司获得新兽药注册证书

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Methylprednisolone Tablets (for dogs), officially classified as a Category 5 new veterinary drug [1] Group 1 - The new veterinary drug, Methylprednisolone Tablets (for dogs), is developed in collaboration with six other companies and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug can be used as part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation in the eyes/ears, as well as other inflammatory/allergic diseases effectively treated with glucocorticoids, including immune-mediated diseases [1]